Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PT
Tweet Send to a Friend
Roth Capital analyst Elemer Piros reiterated a Sell rating and $40.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
